GlobeNewswire

Dragos, a Global Industrial Control System Cybersecurity Startup, Raises $10 Million in Series A Venture Capital

Dela

Funding Provided by Energy Impact Partners, Allegis Capital and DataTribe

Dragos Is Building the First Industrial Cybersecurity Ecosystem

HANOVER, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Dragos Inc., (pronounced Dray-gohs), an industrial control system (ICS) cybersecurity company made up of industry experts with the vision of securing global industrial infrastructure, announced today that it has received a $10 million Series A round of venture capital from co-lead investors Energy Impact Partners (EIP) and Allegis Capital, with additional support from DataTribe, a cybersecurity startup studio that initially funded Dragos.

The Series A round will be used to increase the company's workforce to meet rising customer demand, generated in part through key partnerships with Deloitte, the global audit and financial advisory services firm, and CrowdStrike Inc., a leader in cloud-delivered endpoint protection.

Dragos is the first ICS cybersecurity investment by EIP, which focuses on investments that seek to optimize energy consumption and improve sustainable energy generation.

CRASHOVERRIDE AND DRAGOS REPORT

Dragos has attracted attention for recently producing a report on CRASHOVERRIDE, the malware used to temporarily interrupt power in the Ukraine in a widely publicized cyber-attack last December. CRASHOVERRIDE is the only known malware that disrupts the electrical grid and only the fourth known type of malware to be specifically tailored toward ICS overall.

Founded May 2016 and funded until this point with a seed round of $1.2 million from DataTribe, Dragos has built the first industrial cybersecurity ecosystem. This consists of three core offerings and an assessment tool - the Dragos Platform, the Dragos Threat Operations Center, Global ICS Intelligence, and CyberLens network assessment software. This combination gives customers access to technology to monitor and respond to threats in the ICS, along with intelligence to make informed decisions about threats. Services range from threat hunting to incident response, as well as lightweight software for routine assessments.

The company's biggest technological differentiator is its behavioral analytics. Instead of "anomaly detection" and other types of machine learning-driven technologies that are hitting the market, the approach of Dragos is to codify human experience facing human adversaries. It identifies adversary tradecraft and turns it into behavioral analytics. As a result, defenders get context of what is going on and recommendations on what to do next, not merely a series of alerts.

"Dragos exists to safeguard civilization," said Robert M. Lee, the CEO of Dragos.  "Critical infrastructure powers the global economy and the fabric of modern society. We all strongly believe that civilian infrastructure should be off limits to any adversaries, no matter where the infrastructure is located in the world."

Dragos was founded by ICS cybersecurity experts Lee, Jon Lavender and Justin Cavinee, all veterans of the U.S. intelligence community. There they established a first-of-its-kind mission for the U.S. government to identify, analyze and respond to nation-states launching ICS-focused cyberattacks.

"Industrial control systems are unique unto themselves - hybrid digital and analog environments with very different operational temperaments," said Bob Ackerman, the founder and a Managing Director of cybersecurity investment specialist Allegis Capital. "Unless you have lived your life in this environment, you can't truly appreciate how different or complex ICS systems are.  With Dragos, we invested in the "A" team."

"Protecting the integrity of the grid has always been a top priority for utility operators," said Sameer Reddy, a Vice President at EIP and co-leader of the Series A financing. "One of the critical challenges is access to sufficient human capital. The Dragos platform, which is built and managed by true ICS cybersecurity experts, provides significant force multiplication to ICS operators around the world."

"Energy is essential to our economy and way of life. As a result, energy infrastructure is increasingly a target," said Thomas A. Fanning, Chairman, President and CEO of Southern Company. "As a founding investor in Energy Impact Partners, Southern Company is proud to support enhancing the resiliency of critical infrastructure, in order to better protect the communities where we live and serve."

About Dragos Inc.

Dragos Inc., based in Hanover, Md., is the trusted authority on threats to industrial networks (ICS/IoT). The Dragos Platform is an on-premise or cloud-based security technology that continually and passively collects data to perform asset identification, detects cyber threats through industrial specific behavioral analytics, and enables better efficiency and effectiveness of security personnel through the codification of automated workflows, best practices and incident response procedures. The Dragos Platform is continually enhanced through the Dragos Threat Operations Center, a team of experts providing services that include incident response, threat hunting, and compromise assessments. Both are backed by Dragos Intelligence, which allows for the analysis of adversary intrusions and provides the industry with weekly threat intelligence reports and adds new behavioral analytics to the Dragos Platform. For more information, visit https://dragos.com.

About Energy Impact Partners

Energy Impact Partners is a collaborative strategic investment firm that invests in companies optimizing energy consumption and improving sustainable energy generation. Through close collaboration with its strategic investor base, EIP seeks to bring the best companies, buying power and vision in the industry to bear on the emerging energy landscape. EIP's utility partners include Southern Company, National Grid, Xcel Energy, Ameren, Great Plains Energy, Fortis Inc., AGL, Avista, MGE Energy Inc., TEPCO, PTT Public Company Limited, OGE Energy Corp., TransCanada, and Alliant Energy. For more information, visit www.energyimpactpartners.com.

About Allegis Capital 

Allegis Capital is a premier, early-stage venture firm that invests solely in cybersecurity and was the first venture fund to focus strictly on cyber. In addition to Dragos, current investments include Area 1, Bracket Computing, Callsign, Cyber GRX, E8 Security, RedOwl, Shape Security, Signifyd, Synack, tCell.io and vArmour. Allegis is also a founding partner in DataTribe, a cybersecurity startup studio based in Fulton, Maryland. Allegis Capital is based in San Francisco. For more information, visit www.allegiscap.com or Twitter at @AllegisCapital.

About DataTribe

DataTribe, based in Fulton, Maryland, and Silicon Valley, is a cybersecurity startup studio formed with the mission of combining breakthrough innovation in cybersecurity, Big Data and analytics. The technological base of its startups emerge from federal agencies, such as the National Security Agency, or from government research labs.  DataTribe draws upon Silicon Valley start-up expertise to help create, define and lead new market segments. As an operating company, it directly takes on the task of building startups from concept to initial customer deployments while significantly lowering risk and preserving returns. For more information, visit www.datatribe.com.

For media inquiries, contact Jennifer Jones at jennifer@jenniferjones.com.

Cell: 650-465-5831




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Dragos via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum